<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37334371</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>The value of Interferon &#x3b2; in multiple sclerosis and novel opportunities for its anti-viral activity: a narrative literature review.</ArticleTitle><Pagination><StartPage>1161849</StartPage><MedlinePgn>1161849</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1161849</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1161849</ELocationID><Abstract><AbstractText>Interferon-beta (IFN-&#x3b2;) for Multiple Sclerosis (MS) is turning 30. The COVID-19 pandemic rejuvenated the interest in interferon biology in health and disease, opening translational opportunities beyond neuroinflammation. The antiviral properties of this molecule are in accord with the hypothesis of a viral etiology of MS, for which a credible culprit has been identified in the Epstein-Barr Virus. Likely, IFNs are crucial in the acute phase of SARS-CoV-2 infection, as demonstrated by inherited and acquired impairments of the interferon response that predispose to a severe COVID-19 course. Accordingly, IFN-&#x3b2; exerted protection against SARS-CoV-2 in people with MS (pwMS). In this viewpoint, we summarize the evidence on IFN-&#x3b2; mechanisms of action in MS with a focus on its antiviral properties, especially against EBV. We synopsize the role of IFNs in COVID-19 and the opportunities and challenges of IFN-&#x3b2; usage for this condition. Finally, we leverage the lessons learned in the pandemic to suggest a role of IFN-&#x3b2; in long-COVID-19 and in special MS subpopulations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Bellucci, Albanese, Rizzi, Rinaldi, Salvetti and Ristori.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bellucci</LastName><ForeName>Gianmarco</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Mental Health and Sensory Organs, Centre for Experimental Neurological Therapies (CENTERS), Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albanese</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Merck Serono S.p.A., An Affiliate of Merck KGaA, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzi</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Merck Serono S.p.A., An Affiliate of Merck KGaA, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Mental Health and Sensory Organs, Centre for Experimental Neurological Therapies (CENTERS), Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvetti</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Mental Health and Sensory Organs, Centre for Experimental Neurological Therapies (CENTERS), Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Neurologico Mediterraneo Neuromed, Pozzilli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ristori</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Mental Health and Sensory Organs, Centre for Experimental Neurological Therapies (CENTERS), Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroimmunology Unit, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>77238-31-4</RegistryNumber><NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epstein-Barr virus</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immune cells</Keyword><Keyword MajorTopicYN="N">interferon &#x3b2;</Keyword><Keyword MajorTopicYN="N">multiple Sclerosis</Keyword></KeywordList><CoiStatement>MS receives research support and has received fees as speaker from Sanofi, Biogen, Roche, Novartis, Bayer Schering, and Merck Serono. VR, GB and GR declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. AA and CR are employees of Merck Serono S.p.A., Rome, Italy, an affiliate of Merck KGaA, Darmstadt, Germany.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>3</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37334371</ArticleId><ArticleId IdType="pmc">PMC10275407</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1161849</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Charabati M, Wheeler MA, Weiner HL, Quintana FJ. Multiple sclerosis: neuroimmune crosstalk and therapeutic targeting. Cell (2023) 186:1309&#x2013;27. doi:&#xa0;10.1016/j.cell.2023.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.03.008</ArticleId><ArticleId IdType="pmc">PMC10119687</ArticleId><ArticleId IdType="pubmed">37001498</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. . Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science (2022) 375:296&#x2013;301. doi:&#xa0;10.1126/SCIENCE.ABJ8222/SUPPL_FILE/SCIENCE.ABJ8222_MDAR_REPRODUCIBILITY_CHECKLIST.PDF</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.ABJ8222/SUPPL_FILE/SCIENCE.ABJ8222_MDAR_REPRODUCIBILITY_CHECKLIST.PDF</ArticleId><ArticleId IdType="pubmed">35025605</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. . Clonally expanded b cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature (2022) 603:321&#x2013;7. doi:&#xa0;10.1038/s41586-022-04432-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04432-7</ArticleId><ArticleId IdType="pmc">PMC9382663</ArticleId><ArticleId IdType="pubmed">35073561</ArticleId></ArticleIdList></Reference><Reference><Citation>Aloisi F, Giovannoni G, Salvetti M. Epstein-Barr Virus as a cause of multiple sclerosis: opportunities for prevention and therapy. Lancet Neurol (2023) 22:338&#x2013;49. doi:&#xa0;10.1016/S1474-4422(22)00471-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(22)00471-9</ArticleId><ArticleId IdType="pubmed">36764322</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugliatti M, Berger T, Hartung HP, Oreja-Guevara C, Bar-Or A. Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations. Curr Opin Neurol (2022) 35:319&#x2013;27. doi:&#xa0;10.1097/WCO.0000000000001066</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000001066</ArticleId><ArticleId IdType="pubmed">35674075</ArticleId></ArticleIdList></Reference><Reference><Citation>Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, et al. . COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies. CNS Drugs (2021) 35:317&#x2013;30. doi:&#xa0;10.1007/S40263-021-00804-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S40263-021-00804-1</ArticleId><ArticleId IdType="pmc">PMC7980129</ArticleId><ArticleId IdType="pubmed">33743151</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, et al. . Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology (2021) 97:E1870&#x2013;85. doi:&#xa0;10.1212/WNL.0000000000012753</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012753</ArticleId><ArticleId IdType="pmc">PMC8601210</ArticleId><ArticleId IdType="pubmed">34610987</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, et al. . Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol (2021) 89:780&#x2013;9. doi:&#xa0;10.1002/ana.26028</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26028</ArticleId><ArticleId IdType="pmc">PMC8013440</ArticleId><ArticleId IdType="pubmed">33480077</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani MP, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M, et al. . COVID-19 severity in multiple sclerosis: putting data into context. Neurology(R) Neuroimmunol Neuroinflamm (2022) 9(1):e1105. doi:&#xa0;10.1212/NXI.0000000000001105</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001105</ArticleId><ArticleId IdType="pmc">PMC8579249</ArticleId><ArticleId IdType="pubmed">34753829</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaffaldano P, Lucisano G, Manni A, Paolicelli D, Patti F, Capobianco M, et al. . Risk of getting COVID-19 in people with multiple sclerosis. Neurol - Neuroimmunol Neuroinflamm (2022) 9:1141. doi:&#xa0;10.1212/NXI.0000000000001141</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001141</ArticleId><ArticleId IdType="pmc">PMC8771668</ArticleId><ArticleId IdType="pubmed">35046084</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, et al. . DMTs and covid-19 severity in MS: a pooled analysis from Italy and France. Ann Clin Trans Neurol (2021) 8(8):1738&#x2013;44. doi:&#xa0;10.1002/ACN3.51408</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ACN3.51408</ArticleId><ArticleId IdType="pmc">PMC8351392</ArticleId><ArticleId IdType="pubmed">34240579</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-Guttman B. Interferon &#x3b2; for multiple sclerosis. Cold Spring Harbor Perspect Med (2018) 9(1):e1105. doi:&#xa0;10.1101/CSHPERSPECT.A032003</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/CSHPERSPECT.A032003</ArticleId><ArticleId IdType="pmc">PMC6211378</ArticleId><ArticleId IdType="pubmed">29311124</ArticleId></ArticleIdList></Reference><Reference><Citation>McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol (2015) 15:87&#x2013;103. doi: 10.1038/nri3787</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3787</ArticleId><ArticleId IdType="pmc">PMC7162685</ArticleId><ArticleId IdType="pubmed">25614319</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacs A, Lindemann J. Virus interference. i. the interferon. Proc R Soc Lond Ser B Biol Sci (1957) 147:258&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">26297790</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 32:513&#x2013;45. doi: 10.1146/annurev-immunol-032713-120231</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032713-120231</ArticleId><ArticleId IdType="pmc">PMC4313732</ArticleId><ArticleId IdType="pubmed">24555472</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo F, Giacomini E, Mechelli R. Interferon-&#x3b2; therapy specifically reduces pathogenic memory b cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis. Immunol Cell Biol (2016) 94:886&#x2013;94. doi:&#xa0;10.1038/icb.2016.55</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2016.55</ArticleId><ArticleId IdType="pubmed">27265253</ArticleId></ArticleIdList></Reference><Reference><Citation>Annibali V, Umeton R, Palermo A, Severa M, Paola M, Giglio S, et al. . Analysis of coding and non-coding transcriptome of peripheral b cells reveals an altered interferon response factor (IRF) -1 pathway in multiple sclerosis patients. J Neuroimmunol (2018) 324:165&#x2013;71. doi:&#xa0;10.1016/j.jneuroim.2018.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2018.09.005</ArticleId><ArticleId IdType="pubmed">30270021</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, Reder AT. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol (2002) 129:205&#x2013;15. doi:&#xa0;10.1016/S0165-5728(02)00182-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(02)00182-0</ArticleId><ArticleId IdType="pubmed">12161037</ArticleId></ArticleIdList></Reference><Reference><Citation>Severa M, Rizzo F, Srinivasan S, Di Dario M, Giacomini E, Buscarinu MC, et al. . A cell type-specific transcriptomic approach to map b cell and monocyte type I interferon-linked pathogenic signatures in multiple sclerosis. J Autoimmun (2019) 101:1&#x2013;16. doi:&#xa0;10.1016/j.jaut.2019.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.04.006</ArticleId><ArticleId IdType="pubmed">31047767</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan S, Severa M, Rizzo F, Menon R, Brini E, Mechelli R, et al. . Transcriptional dysregulation of interferome in experimental and human multiple sclerosis. Sci Rep (2017) 7:8981. doi:&#xa0;10.1038/s41598-017-09286-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09286-y</ArticleId><ArticleId IdType="pmc">PMC5566335</ArticleId><ArticleId IdType="pubmed">28827704</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, et al. . Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 45:1353&#x2013;60. doi:&#xa0;10.1038/ng.2770</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2770</ArticleId><ArticleId IdType="pmc">PMC3832895</ArticleId><ArticleId IdType="pubmed">24076602</ArticleId></ArticleIdList></Reference><Reference><Citation>Patsopoulos NA, Baranzini SE, Santaniello A, Shoostari P, Cotsapas C, Wong G, et al. . Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Sci (New York NY) (2019) 365. doi:&#xa0;10.1126/SCIENCE.AAV7188</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.AAV7188</ArticleId><ArticleId IdType="pmc">PMC7241648</ArticleId><ArticleId IdType="pubmed">31604244</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechelli R, Romano C, Reni&#xe8; R, Manfr&#xe8; G, Buscarinu MC, Romano S, et al. . Viruses and neuroinflammation in multiple sclerosis. Neuroimmunol Neuroinflamm (2021) 8:269. doi:&#xa0;10.20517/2347-8659.2021.01</Citation><ArticleIdList><ArticleId IdType="doi">10.20517/2347-8659.2021.01</ArticleId></ArticleIdList></Reference><Reference><Citation>Damania B, Kenney SC, Raab-Traub N. Epstein-Barr Virus: biology and clinical disease. Cell (2022) 185(20):3652&#x2013;70. doi:&#xa0;10.1016/j.cell.2022.08.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.08.026</ArticleId><ArticleId IdType="pmc">PMC9529843</ArticleId><ArticleId IdType="pubmed">36113467</ArticleId></ArticleIdList></Reference><Reference><Citation>Jog NR, McClain MT, Heinlen LD, Gross T, Towner R, Guthridge JM, et al. . Epstein Barr Virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. J Autoimmun (2019) 1:102332. doi:&#xa0;10.1016/j.jaut.2019.102332</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.102332</ArticleId><ArticleId IdType="pmc">PMC6930324</ArticleId><ArticleId IdType="pubmed">31515129</ArticleId></ArticleIdList></Reference><Reference><Citation>Tengvall K, Huang J, Hellstr&#xf6;m C, Kammer P, Bistr&#xf6;m M, Ayoglu B, et al. . Molecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc Natl Acad Sci United States America (2019) 116:16955&#x2013;60. doi:&#xa0;10.1073/PNAS.1902623116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.1902623116</ArticleId><ArticleId IdType="pmc">PMC6708327</ArticleId><ArticleId IdType="pubmed">31375628</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Addario M, Libermann TA, Xu J, Ahmad A, Menezes J. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human b-lymphocytes via CD21, involving activation of NF-&#x3ba;B and different signaling pathways. J Mol Biol (2001) 308(3):501&#x2013;14. doi:&#xa0;10.1006/jmbi.2001.4589</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.2001.4589</ArticleId><ArticleId IdType="pubmed">11327783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang MS, Kieff E. Epstein-Barr Virus latent genes. Exp Mol Med (2015) 47:e131. doi:&#xa0;10.1038/emm.2014.84</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2014.84</ArticleId><ArticleId IdType="pmc">PMC4314583</ArticleId><ArticleId IdType="pubmed">25613728</ArticleId></ArticleIdList></Reference><Reference><Citation>Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. . Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med (2007) 204(12):2899&#x2013;912. doi:&#xa0;10.1084/jem.20071030</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20071030</ArticleId><ArticleId IdType="pmc">PMC2118531</ArticleId><ArticleId IdType="pubmed">17984305</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, et al. . Epstein&#x2013;Barr Virus in multiple sclerosis: theory and emerging immunotherapies. Trends Mol Med (2019) 8(23):296&#x2013;310. doi:&#xa0;10.1016/j.molmed.2019.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2019.11.003</ArticleId><ArticleId IdType="pmc">PMC7106557</ArticleId><ArticleId IdType="pubmed">31862243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechelli R, Umeton R, Policano C, Annibali V, Coarelli G, Ricigliano VAG, et al. . A &#x201c;Candidate-interactome&#x201d; aggregate analysis of genome-wide association data in multiple sclerosis. PloS One (2013) 8(5):e63300. doi:&#xa0;10.1371/journal.pone.0063300</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0063300</ArticleId><ArticleId IdType="pmc">PMC3655974</ArticleId><ArticleId IdType="pubmed">23696811</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, et al. . Epstein-Barr Virus genetic variants are associated with multiple sclerosis. Neurology (2015) 84(13):1362&#x2013;8. doi: 10.1212/WNL.0000000000001420</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001420</ArticleId><ArticleId IdType="pmc">PMC4388746</ArticleId><ArticleId IdType="pubmed">25740864</ArticleId></ArticleIdList></Reference><Reference><Citation>Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, et al. . Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet (2018) 50:699&#x2013;707. doi:&#xa0;10.1038/s41588-018-0102-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0102-3</ArticleId><ArticleId IdType="pmc">PMC6022759</ArticleId><ArticleId IdType="pubmed">29662164</ArticleId></ArticleIdList></Reference><Reference><Citation>Fierz W. Multiple sclerosis: an example of pathogenic viral interaction? Virol J (2017) 14:42. doi:&#xa0;10.1186/s12985-017-0719-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-017-0719-3</ArticleId><ArticleId IdType="pmc">PMC5330019</ArticleId><ArticleId IdType="pubmed">28241767</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;ry P, Nath A, Cr&#xe9;ange A, Dolei A, Marche P, Gold J, et al. . Human endogenous retroviruses in neurological diseases. Trends Mol Med (2018) 24(4):379&#x2013;94. doi:&#xa0;10.1016/j.molmed.2018.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2018.02.007</ArticleId><ArticleId IdType="pmc">PMC7185488</ArticleId><ArticleId IdType="pubmed">29551251</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;llsberg P, Kusk M, Bech E, Hansen HJ, Jakobsen J, Haahr S. Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity. Acta Neurol Scand (2005) 112:395&#x2013;402. doi:&#xa0;10.1111/j.1600-0404.2005.00516.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2005.00516.x</ArticleId><ArticleId IdType="pubmed">16281923</ArticleId></ArticleIdList></Reference><Reference><Citation>Torkildsen, Nyland H, Myrmel H, Myhr KM. Epstein-Barr Virus reactivation and multiple sclerosis. Eur J Neurol (2008) 15:106&#x2013;8. doi:&#xa0;10.1111/j.1468-1331.2007.02009.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2007.02009.x</ArticleId><ArticleId IdType="pubmed">18042233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wandinger KP, Jabs W, Siekhaus A, Bubel S, Trillenberg P, Wagner HJ, et al. . Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology (2000) 55:178&#x2013;84. doi:&#xa0;10.1212/WNL.55.2.178</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.55.2.178</ArticleId><ArticleId IdType="pubmed">10908887</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange PT, White MC, Damania B. Activation and evasion of innate immunity by gammaherpesviruses. J Mol Biol (2022) 434:167214. doi:&#xa0;10.1016/J.JMB.2021.167214</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JMB.2021.167214</ArticleId><ArticleId IdType="pmc">PMC8863980</ArticleId><ArticleId IdType="pubmed">34437888</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentz GL, Liu R, Hahn AM, Shackelford J, Pagano JS. Epstein-Barr Virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-&#x3b2;. Virology (2010) 402:121&#x2013;8. doi:&#xa0;10.1016/J.VIROL.2010.03.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.VIROL.2010.03.014</ArticleId><ArticleId IdType="pmc">PMC2871977</ArticleId><ArticleId IdType="pubmed">20381110</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Sadaoka T, Krogmann T, Cohen JI. Epstein-Barr Virus (EBV) tegument protein BGLF2 suppresses type I interferon signaling to promote EBV reactivation. J Virol (2020) 94. doi:&#xa0;10.1128/JVI.00258-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00258-20</ArticleId><ArticleId IdType="pmc">PMC7269453</ArticleId><ArticleId IdType="pubmed">32213613</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J-T, Doong S-L, Teng S-C, Lee C-P, Tsai C-H, Chen M-R. Epstein-Barr Virus BGLF4 kinase suppresses the interferon regulatory factor 3 signaling pathway. J Virol (2009) 83:1856&#x2013;69. doi:&#xa0;10.1128/JVI.01099-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01099-08</ArticleId><ArticleId IdType="pmc">PMC2643756</ArticleId><ArticleId IdType="pubmed">19052084</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Fossum E, Joo CH, Inn K-S, Shin YC, Johannsen E, et al. . Epstein-Barr Virus LF2: an antagonist to type I interferon. J Virol (2009) 83:1140&#x2013;6. doi:&#xa0;10.1128/JVI.00602-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00602-08</ArticleId><ArticleId IdType="pmc">PMC2612359</ArticleId><ArticleId IdType="pubmed">18987133</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomini E, Severa M, Rizzo F, Mechelli R, Annibali V, Ristori G, et al. . IFN-&#x3b2; therapy modulates b-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients. Eur J Immunol (2013) 43:1963&#x2013;72. doi:&#xa0;10.1002/eji.201243212</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201243212</ArticleId><ArticleId IdType="pubmed">23636665</ArticleId></ArticleIdList></Reference><Reference><Citation>Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol (2007) 25:587&#x2013;617. doi:&#xa0;10.1146/annurev.immunol.25.022106.141553</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.25.022106.141553</ArticleId><ArticleId IdType="pubmed">17378764</ArticleId></ArticleIdList></Reference><Reference><Citation>Recher M, Lang KS, Navarini A, Hunziker L, Lang PA, Fink K, et al. . Extralymphatic virus sanctuaries as a consequence of potent T-cell activation. Nat Med (2007) 13:1316&#x2013;23. doi:&#xa0;10.1038/nm1670</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1670</ArticleId><ArticleId IdType="pmc">PMC7096094</ArticleId><ArticleId IdType="pubmed">17982463</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, et al. . Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PloS Pathog (2013) 9(4):e1003220. doi:&#xa0;10.1371/journal.ppat.1003220</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003220</ArticleId><ArticleId IdType="pmc">PMC3623710</ArticleId><ArticleId IdType="pubmed">23592979</ArticleId></ArticleIdList></Reference><Reference><Citation>Comabella M, Kakalacheva K, R&#xed;o J, M&#xfc;nz C, Montalban X, L&#xfc;nemann JD. EBV-specific immune responses in patients with multiple sclerosis responding to IFN&#x3b2; therapy. Multiple Sclerosis J (2012) 18:605&#x2013;9. doi:&#xa0;10.1177/1352458511426816</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458511426816</ArticleId><ArticleId IdType="pubmed">22020417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol (2021) 19:141&#x2013;54. doi:&#xa0;10.1038/s41579-020-00459-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. . Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nat 2020 584:7821 (2020) 584:463&#x2013;9. doi:&#xa0;10.1038/s41586-020-2588-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol 2022 20:5 (2022) 20:270&#x2013;84. doi:&#xa0;10.1038/s41579-022-00713-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00713-0</ArticleId><ArticleId IdType="pubmed">35354968</ArticleId></ArticleIdList></Reference><Reference><Citation>Jouvenet N, Goujon C, Banerjee A. Clash of the titans: interferons and SARS-CoV-2. Trends Immunol (2021) 42:1069&#x2013;72. doi:&#xa0;10.1016/j.it.2021.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2021.10.009</ArticleId><ArticleId IdType="pmc">PMC8519778</ArticleId><ArticleId IdType="pubmed">34742657</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, et al. . Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun (2020) 11:3810. doi:&#xa0;10.1038/S41467-020-17665-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41467-020-17665-9</ArticleId><ArticleId IdType="pmc">PMC7392898</ArticleId><ArticleId IdType="pubmed">32733001</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkoff JM, tenOever B. Innate immune evasion strategies of SARS-CoV-2. Nat Rev Microbiol (2023) 21:178&#x2013;94. doi:&#xa0;10.1038/s41579-022-00839-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00839-1</ArticleId><ArticleId IdType="pmc">PMC9838430</ArticleId><ArticleId IdType="pubmed">36631691</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H, Cao Z, Xie X, Zhang X, Chen JYC, Wang H, et al. . Evasion of type I interferon by SARS-CoV-2. Cell Rep (2020) 33:108234. doi:&#xa0;10.1016/j.celrep.2020.108234</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108234</ArticleId><ArticleId IdType="pmc">PMC7501843</ArticleId><ArticleId IdType="pubmed">32979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui L, Zhao Y, Wang W, Wu P, Wang Z, Yu Y, et al. . SARS-CoV-2 membrane protein inhibits type I interferon production through ubiquitin-mediated degradation of TBK1. Front Immunol (2021) 12:662989. doi:&#xa0;10.3389/FIMMU.2021.662989</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2021.662989</ArticleId><ArticleId IdType="pmc">PMC8168463</ArticleId><ArticleId IdType="pubmed">34084167</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, et al. . Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. J Virol (2020) 94(23):e01410&#x2013;20. doi:&#xa0;10.1128/JVI.01410-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01410-20</ArticleId><ArticleId IdType="pmc">PMC7654262</ArticleId><ArticleId IdType="pubmed">32938761</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo K, Barrett BS, Morrison JH, Mickens KL, Vladar EK, Hasenkrug KJ, et al. . Interferon resistance of emerging SARS-CoV-2 variants. Proc Natl Acad Sci United States America (2022) 119:e2203760119. doi:&#xa0;10.1073/PNAS.2203760119/SUPPL_FILE/PNAS.2203760119.SAPP.PDF</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.2203760119/SUPPL_FILE/PNAS.2203760119.SAPP.PDF</ArticleId><ArticleId IdType="pmc">PMC9371743</ArticleId><ArticleId IdType="pubmed">35867811</ArticleId></ArticleIdList></Reference><Reference><Citation>Park A, Iwasaki A. Type I and type III interferons &#x2013; induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe (2020) 27:870&#x2013;8. doi:&#xa0;10.1016/J.CHOM.2020.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CHOM.2020.05.008</ArticleId><ArticleId IdType="pmc">PMC7255347</ArticleId><ArticleId IdType="pubmed">32464097</ArticleId></ArticleIdList></Reference><Reference><Citation>Venet M, Ribeiro MS, D&#xe9;cembre E, Bellomo A, Joshi G, Nuovo C, et al. . Severe COVID-19 patients have impaired plasmacytoid dendritic cell-mediated control of SARS-CoV-2. Nat Commun (2023) 14:694. doi:&#xa0;10.1038/s41467-023-36140-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36140-9</ArticleId><ArticleId IdType="pmc">PMC9907212</ArticleId><ArticleId IdType="pubmed">36755036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. . Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science (2020) 369:718&#x2013;24. doi:&#xa0;10.1126/science.abc6027</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Loske J, R&#xf6;hmel J, Lukassen S, Stricker S, Magalh&#xe3;es VG, Liebig J, et al. . Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat Biotechnol (2022) 40:319&#x2013;24. doi:&#xa0;10.1038/S41587-021-01037-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41587-021-01037-9</ArticleId><ArticleId IdType="pubmed">34408314</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungnak W, Huang N, B&#xe9;cavin C, Berg M, Queen R, Litvinukova M, et al. . SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med (2020) 26:681&#x2013;7. doi:&#xa0;10.1038/s41591-020-0868-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0868-6</ArticleId><ArticleId IdType="pmc">PMC8637938</ArticleId><ArticleId IdType="pubmed">32327758</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M, Worlock KB, Huang N. Local and systemic responses to SARS-CoV-2 infection in children and adults. Nature (2022) 602:321&#x2013;7. doi:&#xa0;10.1038/s41586-021-04345-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04345-x</ArticleId><ArticleId IdType="pmc">PMC8828466</ArticleId><ArticleId IdType="pubmed">34937051</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E. SARS-CoV-2, COVID-19 and the aging immune system. Nat Aging 2021 1:9 (2021) 1:769&#x2013;82. doi:&#xa0;10.1038/s43587-021-00114-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-021-00114-7</ArticleId><ArticleId IdType="pmc">PMC8570568</ArticleId><ArticleId IdType="pubmed">34746804</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Zheng S-N, Xiao Y, Nan M-L, Zhang J, Han L, et al. . SARS-CoV-2 NSP8 suppresses type I and III IFN responses by modulating the RIG-I/MDA5, TRIF, and STING signaling pathways. J Med Virol (2023) 95(4). doi:&#xa0;10.1002/jmv.28680</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28680</ArticleId><ArticleId IdType="pubmed">36929724</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer J, Crotta S, Breithaupt A, Ohnemus A, Becker J, Sachs B, et al. . Impaired immune response drives age-dependent severity of COVID-19. J Exp Med (2022) 219(12):e20220621. doi:&#xa0;10.1084/JEM.20220621</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/JEM.20220621</ArticleId><ArticleId IdType="pmc">PMC9499827</ArticleId><ArticleId IdType="pubmed">36129445</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Bastard P, Karbuz A, Gervais A, Tayoun AA, Aiuti A, et al. . Human genetic and immunological determinants of critical COVID-19 pneumonia. Nat 2022 603:7902 (2022) 603:587&#x2013;98. doi:&#xa0;10.1038/s41586-022-04447-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04447-0</ArticleId><ArticleId IdType="pmc">PMC8957595</ArticleId><ArticleId IdType="pubmed">35090163</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Bastard P, Liu Z. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science (2020) 370:eabd4570. doi:&#xa0;10.1126/science.abd4570. 2020 09 26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4570</ArticleId><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Matuozzo D, Le Pen J, Lee D, Moens L, Asano T, et al. . Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. J Exp Med (2022) 219. doi:&#xa0;10.1084/JEM.20220131/213287</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/JEM.20220131/213287</ArticleId><ArticleId IdType="pmc">PMC9206114</ArticleId><ArticleId IdType="pubmed">35708626</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Renkilaraj MRLM, et al. . X-Linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol (2021) 6:eabl4348. doi:&#xa0;10.1126/sciimmunol.abl4348</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4348</ArticleId><ArticleId IdType="pmc">PMC8532080</ArticleId><ArticleId IdType="pubmed">34413140</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemi MEK, Karjalainen J, Liao RG, Neale BM, Daly M, Ganna A, et al. . Mapping the human genetic architecture of COVID-19. Nature (2021) 600:472&#x2013;7. doi:&#xa0;10.1038/s41586-021-03767-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03767-x</ArticleId><ArticleId IdType="pmc">PMC8674144</ArticleId><ArticleId IdType="pubmed">34237774</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. . Genetic mechanisms of critical illness in COVID-19. Nature (2021) 591:92&#x2013;8. doi:&#xa0;10.1038/s41586-020-03065-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03065-y</ArticleId><ArticleId IdType="pubmed">33307546</ArticleId></ArticleIdList></Reference><Reference><Citation>Matuozzo D, Talouarn E, Marchal A, Zhang P, Manry J, Seeleuthner Y, et al. . Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Genome Med (2023) 15:22. doi:&#xa0;10.1186/s13073-023-01173-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-023-01173-8</ArticleId><ArticleId IdType="pmc">PMC10074346</ArticleId><ArticleId IdType="pubmed">37020259</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;iz-Banciella MG, Albaiceta GM, Amado-Rodr&#xed;guez L, Del Riego ES, Alonso IL, L&#xf3;pez-Mart&#xed;nez C, et al. . Age-dependent effect of the IFIH1/MDA5 gene variants on the risk of critical COVID-19. Immunogenetics (2023) 75:91&#x2013;8. doi:&#xa0;10.1007/s00251-022-01281-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-022-01281-6</ArticleId><ArticleId IdType="pmc">PMC9702716</ArticleId><ArticleId IdType="pubmed">36434151</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado-Rodr&#xed;guez L, Salgado Del Riego E, Gomez de Ona J, L&#xf3;pez Alonso I, Gil-Pena H, L&#xf3;pez-Mart&#xed;nez C, et al. . Effects of IFIH1 rs1990760 variants on systemic inflammation and outcome in critically ill COVID-19 patients in an observational translational study. Elife (2022) 11:e73012. doi:&#xa0;10.7554/eLife.73012</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.73012</ArticleId><ArticleId IdType="pmc">PMC8782569</ArticleId><ArticleId IdType="pubmed">35060899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Gervais A, Voyer TL, Rosain J, Philippot Q, Manry J, et al. . Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol (2021) 6:eabl4340. doi:&#xa0;10.1126/sciimmunol.abl4340</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4340</ArticleId><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasca F, Scordio M, Santinelli L, Gabriele L, Gandini O, Criniti A, et al. . Anti-IFN-&#x3b1;/-&#x3c9; neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity. Eur J Immunol (2022) 52:1120&#x2013;8. doi:&#xa0;10.1002/EJI.202249824</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/EJI.202249824</ArticleId><ArticleId IdType="pmc">PMC9087404</ArticleId><ArticleId IdType="pubmed">35419822</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves D, Mezidi M, Bastard P, Perret M, Saker K, Fabien N, et al. . Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. Clin Trans Immunol (2021) 10(8):e1327. doi:&#xa0;10.1002/CTI2.1327</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/CTI2.1327</ArticleId><ArticleId IdType="pmc">PMC8370568</ArticleId><ArticleId IdType="pubmed">34429968</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, et al. . Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med (2021) 13:eabh2624. doi:&#xa0;10.1126/SCITRANSLMED.ABH2624</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCITRANSLMED.ABH2624</ArticleId><ArticleId IdType="pmc">PMC8601717</ArticleId><ArticleId IdType="pubmed">34429372</ArticleId></ArticleIdList></Reference><Reference><Citation>Troya J, Bastard P, Planas-Serra L, Ryan P, Ruiz M, de Carranza M, et al. . Neutralizing autoantibodies to type I IFNs in &gt;10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. J Clin Immunol (2021) 41:914&#x2013;22. doi:&#xa0;10.1007/S10875-021-01036-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S10875-021-01036-0</ArticleId><ArticleId IdType="pmc">PMC8043439</ArticleId><ArticleId IdType="pubmed">33851338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale BG. Autoantibodies targeting type I interferons: prevalence, mechanisms of induction, and association with viral disease susceptibility. Eur J Immunol (2023), e2250164. doi:&#xa0;10.1002/eji.202250164</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202250164</ArticleId><ArticleId IdType="pubmed">37027328</ArticleId></ArticleIdList></Reference><Reference><Citation>Crichton ML, Goeminne PC, Tuand K, Vandendriessche T, Tonia T, Roche N, et al. . The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European respiratory society living guideline. Eur Respir Rev (2021) 30. doi:&#xa0;10.1183/16000617.0171-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0171-2021</ArticleId><ArticleId IdType="pmc">PMC8796659</ArticleId><ArticleId IdType="pubmed">34911695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Saurabh MK, Narasimha VL, Maharshi V. Efficacy of interferon-&#x3b2; in moderate-to-Severe hospitalised cases of COVID-19: a systematic review and meta-analysis. Clin Drug Invest (2021) 41:1037&#x2013;46. doi:&#xa0;10.1007/S40261-021-01092-9/TABLES/2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S40261-021-01092-9/TABLES/2</ArticleId><ArticleId IdType="pmc">PMC8540871</ArticleId><ArticleId IdType="pubmed">34687413</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakhlband A, Fakhari A, Azizi H. Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies. Naunyn-Schmiedeberg&#x2019;s Arch Pharmacol (2021) 394:829&#x2013;38. doi:&#xa0;10.1007/S00210-021-02061-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00210-021-02061-X</ArticleId><ArticleId IdType="pmc">PMC7883756</ArticleId><ArticleId IdType="pubmed">33587164</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosa JP, Caceres MMF, Comptis JR, Quiros J, Pr&#xed;ncipe-Meneses FS, Riva-Moscoso A, et al. . Effects of interferon beta in covid-19 adult patients: systematic review. Infection Chemother (2021) 53:247&#x2013;60. doi:&#xa0;10.3947/IC.2021.0028</Citation><ArticleIdList><ArticleId IdType="doi">10.3947/IC.2021.0028</ArticleId><ArticleId IdType="pmc">PMC8258298</ArticleId><ArticleId IdType="pubmed">34216119</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryoo S, Koh D-H, Yu S-Y, Choi M, Huh K, Yeom J-S, et al. . Clinical efficacy and safety of interferon (Type I and type III) therapy in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. PloS One (2023) 18:e0272826. doi:&#xa0;10.1371/journal.pone.0272826</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0272826</ArticleId><ArticleId IdType="pmc">PMC10057835</ArticleId><ArticleId IdType="pubmed">36989209</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalkanen J, Pettil&#xe4; V, Huttunen T, Hollm&#xe9;n M, Jalkanen S. Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung. Intensive Care Med (2020) 46:1937&#x2013;40. doi:&#xa0;10.1007/S00134-020-06086-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00134-020-06086-3</ArticleId><ArticleId IdType="pmc">PMC7235433</ArticleId><ArticleId IdType="pubmed">32430515</ArticleId></ArticleIdList></Reference><Reference><Citation>Akamatsu MA, de Castro JT, Takano CY, Ho PL. Off balance: interferons in COVID-19 lung infections. EBioMedicine (2021) 73. doi:&#xa0;10.1016/J.EBIOM.2021.103642</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.EBIOM.2021.103642</ArticleId><ArticleId IdType="pmc">PMC8524139</ArticleId><ArticleId IdType="pubmed">34678609</ArticleId></ArticleIdList></Reference><Reference><Citation>Galani IE, Rovina N, Lampropoulou V, Triantafyllia V, Manioudaki M, Pavlos E, et al. . Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat Immunol (2021) 22:32&#x2013;40. doi:&#xa0;10.1038/S41590-020-00840-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41590-020-00840-X</ArticleId><ArticleId IdType="pubmed">33277638</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, et al. . Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med (2021) 9:1365&#x2013;76. doi:&#xa0;10.1016/S2213-2600(21)00384-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00384-2</ArticleId><ArticleId IdType="pmc">PMC8523116</ArticleId><ArticleId IdType="pubmed">34672949</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbraith MD, Kinning KT, Sullivan KD, Araya P, Smith KP, Granrath RE, et al. . Specialized interferon action in COVID-19. Proc Natl Acad Sci United States America (2022) 119(11):e2116730119. doi:&#xa0;10.1073/PNAS.2116730119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.2116730119</ArticleId><ArticleId IdType="pmc">PMC8931386</ArticleId><ArticleId IdType="pubmed">35217532</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif D, Ejghal R, Desterke C, Outlioua A, Hammi I, Lemrani M, et al. . Type I and III interferons are good markers to monitor COVID-19 pathophysiology. Cytokine (2023) 165:156172. doi:&#xa0;10.1016/j.cyto.2023.156172</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2023.156172</ArticleId><ArticleId IdType="pmc">PMC10008794</ArticleId><ArticleId IdType="pubmed">36924609</ArticleId></ArticleIdList></Reference><Reference><Citation>Berri F, N&#x2019;Guyen Y, Callon D, Lebreil A-L, Glenet M, Heng L, et al. . Early plasma interferon-&#x3b2; levels as a predictive marker of COVID-19 severe clinical events in adult patients. J Med Virol (2023) 95:e28361. doi:&#xa0;10.1002/jmv.28361</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28361</ArticleId><ArticleId IdType="pmc">PMC9877952</ArticleId><ArticleId IdType="pubmed">36451263</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, et al. . Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol (2019) 76(5):536&#x2013;41. doi:&#xa0;10.1001/jamaneurol.2018.4905</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.4905</ArticleId><ArticleId IdType="pmc">PMC6515582</ArticleId><ArticleId IdType="pubmed">30776055</ArticleId></ArticleIdList></Reference><Reference><Citation>Prosperini L, Mancinelli CR, Solaro CM, Nociti V, Haggiag S, Cordioli C, et al. . Induction versus escalation in multiple sclerosis: a 10-year real world study. Neurotherapeutics (2020) 17:994&#x2013;1004. doi:&#xa0;10.1007/s13311-020-00847-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-020-00847-0</ArticleId><ArticleId IdType="pmc">PMC7609676</ArticleId><ArticleId IdType="pubmed">32236822</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova B, Quintanilla-Bord&#xe1;s C, Gasc&#xf3;n F. Escalation vs. early intense therapy in multiple sclerosis. J Pers Med (2022) 12:119. doi:&#xa0;10.3390/jpm12010119</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12010119</ArticleId><ArticleId IdType="pmc">PMC8778390</ArticleId><ArticleId IdType="pubmed">35055434</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger T, Adamczyk-Sowa M, Cs&#xe9;p&#xe1;ny T, Fazekas F, Fabjan TH, Hor&#xe1;kov&#xe1; D, et al. . Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. Ther Adv Neurol Disord (2020) 13:1756286420975223. doi:&#xa0;10.1177/1756286420975223</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756286420975223</ArticleId><ArticleId IdType="pmc">PMC7724259</ArticleId><ArticleId IdType="pubmed">33335562</ArticleId></ArticleIdList></Reference><Reference><Citation>Varyt&#x117; G, Arlauskien&#x117; A, Rama&#x161;auskait&#x117; D. Pregnancy and multiple sclerosis: an update. Curr Opin Obstet Gynecol (2021) 33:378&#x2013;83. doi:&#xa0;10.1097/GCO.0000000000000731</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GCO.0000000000000731</ArticleId><ArticleId IdType="pmc">PMC8452312</ArticleId><ArticleId IdType="pubmed">34310364</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans C, Zhu F, Kingwell E, Shirani A, van der Kop ML, Petkau J, et al. . Association between beta-interferon exposure and hospital events in multiple sclerosis. Pharmacoepidemiol Drug Saf (2014) 23:1213&#x2013;22. doi:&#xa0;10.1002/pds.3667</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3667</ArticleId><ArticleId IdType="pubmed">24953054</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhib-Jalbut S, Marks S. Interferon-&#x3b2; mechanisms of action in multiple sclerosis. Neurology (2010) 74. doi:&#xa0;10.1212/WNL.0B013E3181C97D99</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0B013E3181C97D99</ArticleId><ArticleId IdType="pubmed">20038758</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong HJI, Kingwell E, Shirani A, Cohen Tervaert JW, Hupperts R, Zhao Y, et al. . Evaluating the safety of &#x3b2;-interferons in MS: a series of nested case-control studies. Neurology (2017) 88:2310&#x2013;20. doi:&#xa0;10.1212/WNL.0000000000004037</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004037</ArticleId><ArticleId IdType="pmc">PMC5567323</ArticleId><ArticleId IdType="pubmed">28500224</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikonen MK, Er&#xe4;linna JP. Beta-interferon protects multiple sclerosis patients against enhanced susceptibility to infections caused by poor air quality. Neuroepidemiology (2008) 30:13&#x2013;9. doi:&#xa0;10.1159/000113301</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000113301</ArticleId><ArticleId IdType="pubmed">18204292</ArticleId></ArticleIdList></Reference><Reference><Citation>Prosperini L, Lucchini M, Ruggieri S, Tortorella C, Haggiag S, Mirabella M, et al. . Shift of multiple sclerosis onset towards older age. J Neurol Neurosurg Psychiatry (2022) 93:1137&#x2013;9. doi:&#xa0;10.1136/JNNP-2022-329049</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/JNNP-2022-329049</ArticleId><ArticleId IdType="pubmed">35477891</ArticleId></ArticleIdList></Reference><Reference><Citation>Buscarinu MC, Reni&#xe8; R, Morena E, Romano C, Bellucci G, Marrone A, et al. . Late-onset MS: disease course and safety-efficacy of DMTS. Front Neurol (2022) 13:829331/BIBTEX. doi:&#xa0;10.3389/FNEUR.2022.829331/BIBTEX</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FNEUR.2022.829331/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC8960027</ArticleId><ArticleId IdType="pubmed">35356454</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng E, Balint E, Poznanski SM, Ashkar AA, Loeb M. Aging and interferons: impacts on inflammation and viral disease outcomes. Cells (2021) 10(3):708. doi:&#xa0;10.3390/CELLS10030708</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/CELLS10030708</ArticleId><ArticleId IdType="pmc">PMC8004738</ArticleId><ArticleId IdType="pubmed">33806810</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao W. IFN-aging: coupling aging with interferon response. Front Aging (2022) 0:870489. doi:&#xa0;10.3389/FRAGI.2022.870489</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FRAGI.2022.870489</ArticleId><ArticleId IdType="pmc">PMC9261325</ArticleId><ArticleId IdType="pubmed">35821859</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L, Chen J, Lo CYZ, Guo Q, Feng J, Zhao XM. Impaired type I interferon signaling activity implicated in the peripheral blood transcriptome of preclinical alzheimer&#x2019;s disease. eBioMedicine (2022) 82. doi:&#xa0;10.1016/j.ebiom.2022.104175</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104175</ArticleId><ArticleId IdType="pmc">PMC9304603</ArticleId><ArticleId IdType="pubmed">35863293</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano S, Ferraldeschi M, Bagnato F, Mechelli R, Morena E, Caldano M, et al. . Drug holiday of interferon beta 1b in multiple sclerosis: a pilot, randomized, single blind study of non-inferiority. Front Neurol (2019) 10:695. doi:&#xa0;10.3389/fneur.2019.00695</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00695</ArticleId><ArticleId IdType="pmc">PMC6646514</ArticleId><ArticleId IdType="pubmed">31379701</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. . Post-acute COVID-19 syndrome. Nat Med 2021 27:4 (2021) 27:601&#x2013;15. doi:&#xa0;10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis (2022) 226(9):1593&#x2013;607. doi:&#xa0;10.1093/INFDIS/JIAC136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/INFDIS/JIAC136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med (2022) 28:911&#x2013;23. doi:&#xa0;10.1038/s41591-022-01810-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens (Basel Switzerland) (2021) 10(6):763. doi:&#xa0;10.3390/PATHOGENS10060763</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/PATHOGENS10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell (2022) 185:881&#x2013;895.e20. doi:&#xa0;10.1016/J.CELL.2022.01.014/ATTACHMENT/B1FB9AE1-6442-495C-A1DF-6A5E16CA88FA/MMC7.XLSX</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2022.01.014/ATTACHMENT/B1FB9AE1-6442-495C-A1DF-6A5E16CA88FA/MMC7.XLSX</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci G, Rinaldi V, Buscarinu MC, Reni&#xe8; R, Bigi R, Pellicciari G, et al. . Multiple sclerosis and SARS-CoV-2: has the interplay started? Front Immunol (2021) 12:755333. doi:&#xa0;10.3389/fimmu.2021.755333</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.755333</ArticleId><ArticleId IdType="pmc">PMC8503550</ArticleId><ArticleId IdType="pubmed">34646278</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>